Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Inventory (2020 - 2025)

Historic Inventory for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $67.5 million.

  • Xeris Biopharma Holdings' Inventory rose 4952.02% to $67.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.5 million, marking a year-over-year increase of 4952.02%. This contributed to the annual value of $48.2 million for FY2024, which is 2404.09% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Inventory stood at $67.5 million, which was up 4952.02% from $67.3 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Inventory ranged from a high of $67.5 million in Q3 2025 and a low of $14.2 million during Q3 2021
  • In the last 5 years, Xeris Biopharma Holdings' Inventory had a median value of $38.1 million in 2023 and averaged $36.4 million.
  • Its Inventory has fluctuated over the past 5 years, first skyrocketed by 11690.41% in 2021, then skyrocketed by 1762.27% in 2024.
  • Over the past 5 years, Xeris Biopharma Holdings' Inventory (Quarter) stood at $18.1 million in 2021, then soared by 36.52% to $24.7 million in 2022, then surged by 57.02% to $38.8 million in 2023, then grew by 24.04% to $48.2 million in 2024, then surged by 40.04% to $67.5 million in 2025.
  • Its last three reported values are $67.5 million in Q3 2025, $67.3 million for Q2 2025, and $52.7 million during Q1 2025.